- Home
- STTK vs HQI Comparison
STTK vs HQI Comparison
Compare STTK & HQI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- HQI
- Stock Information
- Founded
- STTK 2016
- HQI 2002
- Country
- STTK United States
- HQI United States
- Employees
- STTK N/A
- HQI N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- HQI Professional Services
- Sector
- STTK Health Care
- HQI Consumer Discretionary
- Exchange
- STTK Nasdaq
- HQI Nasdaq
- Market Cap
- STTK 173.6M
- HQI 172.8M
- IPO Year
- STTK 2020
- HQI N/A
- Fundamental
- Price
- STTK $3.84
- HQI $14.48
- Analyst Decision
- STTK Strong Buy
- HQI Strong Buy
- Analyst Count
- STTK 3
- HQI 2
- Target Price
- STTK $10.67
- HQI $18.00
- AVG Volume (30 Days)
- STTK 123.8K
- HQI 18.7K
- Earning Date
- STTK 11-07-2024
- HQI 11-06-2024
- Dividend Yield
- STTK N/A
- HQI 1.76%
- EPS Growth
- STTK N/A
- HQI N/A
- EPS
- STTK N/A
- HQI 0.37
- Revenue
- STTK $4,123,999.00
- HQI $36,133,000.00
- Revenue This Year
- STTK $164.45
- HQI N/A
- Revenue Next Year
- STTK N/A
- HQI $7.62
- P/E Ratio
- STTK N/A
- HQI $37.50
- Revenue Growth
- STTK 380.09
- HQI 3.96
- 52 Week Low
- STTK $1.33
- HQI $11.39
- 52 Week High
- STTK $11.76
- HQI $17.45
- Technical
- Relative Strength Index (RSI)
- STTK 53.41
- HQI 58.63
- Support Level
- STTK $3.63
- HQI $13.46
- Resistance Level
- STTK $3.94
- HQI $14.73
- Average True Range (ATR)
- STTK 0.22
- HQI 0.60
- MACD
- STTK 0.06
- HQI 0.02
- Stochastic Oscillator
- STTK 64.91
- HQI 87.50
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The primary source of revenue for the company is royalty fees based on the operation of its franchised offices.